Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Assets (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Current Assets for 12 consecutive years, with $715.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 21.12% to $715.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $715.6 million through Dec 2025, down 21.12% year-over-year, with the annual reading at $715.6 million for FY2025, 21.12% down from the prior year.
  • Current Assets hit $715.6 million in Q4 2025 for Viking Therapeutics, down from $738.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $966.3 million in Q1 2024 to a low of $149.5 million in Q1 2023.
  • Historically, Current Assets has averaged $491.4 million across 5 years, with a median of $374.3 million in 2023.
  • Biggest five-year swings in Current Assets: decreased 26.37% in 2022 and later soared 546.52% in 2024.
  • Year by year, Current Assets stood at $210.5 million in 2021, then dropped by 20.66% to $167.0 million in 2022, then soared by 119.84% to $367.2 million in 2023, then skyrocketed by 147.05% to $907.2 million in 2024, then dropped by 21.12% to $715.6 million in 2025.
  • Business Quant data shows Current Assets for VKTX at $715.6 million in Q4 2025, $738.7 million in Q3 2025, and $827.0 million in Q2 2025.